Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity-Reference-Cited by-同舟云学术

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

Published:2005-11 Issue:11 Volume:29 Page:1253-1257
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Flinn Ian W.,Byrd John C.,Bartlett Nancy,Kipps Thomas,Gribben John,Thomas Deborah,Larson Richard A.,Rai Kanti,Petric Rosemary,Ramon-Suerez Jose,Gabrilove Janice,Grever Michael R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia;Johnson;Lancet,1996

2. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients;Leporrier;Blood,2001

3. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia;Rai;N Engl J Med,2000

4. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukaemia;O’Brien;J Clin Oncol,2001

5. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies;Flinn;Blood,2000

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel benzo chromene derivatives: design, synthesis, molecular docking, cell cycle arrest, and apoptosis induction in human acute myeloid leukemia HL-60 cells;Journal of Enzyme Inhibition and Medicinal Chemistry;2022-12-02

2. From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy;Journal of Medicinal Chemistry;2022-04-29

3. Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors;ACS Medicinal Chemistry Letters;2021-06-22

4. Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia;Journal of Controlled Release;2021-05

5. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3 mimetic resistance in lymphomas;Blood;2020-12-01